NasdaqGS - Delayed Quote • USD
Atara Biotherapeutics, Inc. (ATRA)
At close: May 14 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -0.12 | -0.15 | -0.61 | -0.56 |
| Low Estimate | -0.18 | -0.27 | -0.82 | -1.25 |
| High Estimate | -0.03 | -0.04 | -0.4 | 0.16 |
| Year Ago EPS | -0.68 | -0.66 | -2.61 | -0.61 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | 32.21M | 24.89M | 114.67M | 101.23M |
| Low Estimate | 16M | -- | 76.9M | 16M |
| High Estimate | 47.36M | 47.36M | 149.43M | 153.38M |
| Year Ago Sales | 3.77M | 4.76M | 8.57M | 114.67M |
| Sales Growth (year/est) | 754.40% | 422.90% | 1,237.60% | -11.70% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.67 | -0.66 | -0.48 | -0.26 |
| EPS Actual | -0.68 | -0.66 | -0.56 | -0.23 |
| Difference | -0.01 | 0 | -0.08 | 0.03 |
| Surprise % | -1.50% | 0.00% | -16.70% | 11.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.12 | -0.15 | -0.61 | -0.56 |
| 7 Days Ago | -0.14 | -0.26 | -0.72 | -0.46 |
| 30 Days Ago | -0.14 | -0.26 | -0.69 | -0.55 |
| 60 Days Ago | -0.35 | -0.38 | -1.48 | -1.09 |
| 90 Days Ago | -0.35 | -0.38 | -1.48 | -1.09 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 2 | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | 2 |
Growth Estimates
| CURRENCY IN USD | ATRA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 82.40% | -- | -- | 7.30% |
| Next Qtr. | 77.30% | -- | -- | 10.90% |
| Current Year | 76.60% | -- | -- | 4.60% |
| Next Year | 8.20% | -- | -- | 13.00% |
| Next 5 Years (per annum) | -- | -- | -- | 10.89% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Stifel: Hold to Hold | 4/1/2024 |
| Maintains | Goldman Sachs: Sell to Sell | 11/10/2023 |
| Downgrade | Evercore ISI Group: Outperform to In-Line | 11/9/2023 |
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 11/9/2023 |
| Downgrade | Mizuho: Buy to Neutral | 11/9/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/26/2023 |
Related Tickers
KPTI Karyopharm Therapeutics Inc.
1.0900
-2.68%
ALLK Allakos Inc.
1.1900
-2.46%
ALLO Allogene Therapeutics, Inc.
2.9600
+2.07%
FGEN FibroGen, Inc.
1.1800
-2.48%
SGMO Sangamo Therapeutics, Inc.
0.5679
+2.99%
KZR Kezar Life Sciences, Inc.
0.7895
+5.62%
ACHL Achilles Therapeutics plc
0.9200
+3.94%
LPTX Leap Therapeutics, Inc.
2.7500
-2.83%
GTHX G1 Therapeutics, Inc.
4.6500
+0.65%
ADAP Adaptimmune Therapeutics plc
1.1500
-1.71%